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Smoking and COPD: 
Endothelium-Related and 
Neuro-mediated Emphysema 
Mechanisms
Vera Nevzorova, Tatiana Brodskaya and Eugeny Gilifanov
Abstract
This chapter describes endothelium-related and neuro-mediated mechanisms 
of emphysema development in chronic obstructive pulmonary disease (COPD) 
and smoking on the basis of previously completed studies, literature data, and 
own researches. As components of neurogenic inflammation in the processes of 
tissue remodeling in emphysema, we describe the distribution and activity of the 
substance P, neurokinin-1 and its receptor, tissue metalloproteinases and their 
tissue inhibitors in the lungs during the entire experimental period, the modeling 
of COPD in rats with a smoking model. We also analyzed the content of neuroki-
nin system markers, the localization, and markers of tissue metalloproteinases in 
human lung tissue structures. We have confidence that there is a special morpho-
functional continuum of development of lower respiratory tract remodeling in 
response to chronic exposure to tobacco smoke and the development of inflamma-
tion in COPD. New data suggest that imbalance of neuro-mediated interactions, 
alteration of vasomotoric signaling mechanisms, secretion, mucociliary clearance, 
cytoprotection involving substance P-dependent components with impaired 
content, and development of dystopia of matrix metalloproteinases and their tissue 
inhibitors are involved in the initiation of morphological restructuring. Research 
in this direction should be continued to allow approaches to the development of 
preventive and therapeutic strategies for emphysema.
Keywords: COPD, smoking, emphysema, remodeling, neuro-mediated, 
endothelium, neurokinins, metalloproteinases
1. Introduction
Emphysema, or destruction of the gas-exchanging surfaces of the alveoli, is one 
of the typical manifestations of chronic obstructive pulmonary disease (COPD). 
Emphysema is a pathological term that is often used clinicaly, has great medical 
significance and describes only one of several structural abnormalities present 
in patients [1]. Many previous definitions of COPD have emphasized the terms 
“emphysema” and “chronic bronchitis,” which are not included in the definition 
used in the last GOLD report. In GOLD 2018, COPD was defined as a common, 
preventable, and treatable disease that is characterized by persistent respiratory 
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symptoms and airflow limitation that is due to airway and/or alveolar abnormali-
ties usually caused by significant exposure to noxious particles or gases [1]. It 
was mentioned that chronic respiratory symptoms also exist in individuals with 
normal spirometry and a significant number of smokers without airflow limitation 
have structural evidence of lung disease manifested by the varying presence of 
emphysema, airway wall thickening, and gas trapping [2–4]. Really, smoking is a 
major risk factor for COPD, and it plays an important role in lung tissue destruc-
tion development. Some experiments prove that aggressive pollutants of tobacco 
smoke (benzopyrene, peroxynitrite, acrolein, cyanides, peroxides, etc.) can cause 
direct damage to endothelial cells due to expression of adhesion molecules on their 
surface and intensification of lipid peroxidation [2, 5–7]. But the main underly-
ing cause of structural changes is chronic inflammation, which is confirmed 
by numerous studies [1, 4–6]. Even in mild COPD, or in smokers susceptible to 
emphysema [7, 8], there are significant abnormalities in pulmonary microvascular 
blood flow that worsen with disease progression [9].
It was proven that vascular endothelium actively participates in inflammatory 
reactions in COPD [10–13]. It was a systemized data about cigarette smoke as an 
endothelial toxin and activator [14]. Endothelium is one of the direct participants 
of development and maintenance of chronic inflammation. Oxidized lipoproteins 
in the tunica intima of the vessel work as attractants for chemotaxis of leukocytes 
and monocytes that start to produce pro-inflammatory cytokines in big amounts. 
These processes trigger systemic inflammatory response that leads to irreversible 
thickening of the vessel walls and deterioration of their mechanical properties. 
Chronic exposure to tobacco smoke and the products of combustion of tobacco lead 
to chronic system inflammatory reaction, oxidative stress, endothelial dysfunction, 
and morphofunctional damage of target organs. Nowadays the connection between 
endothelium-related mechanisms and emphysema forming, and progression in 
COPD is well known. Recent studies are approaching the description of the neuro-
mediated mechanisms of emphysema development in COPD.
In this chapter we have analyzed data from researchers and shared our own 
research on the study of endothelium and the neuro-mediated mechanisms of 
emphysema development  in COPD and smoking.
2.  Endothelium-related and neuro-mediated mechanisms of emphysema 
development in COPD and smoking: research data
The participation of endothelial dysfunction and injury in emphysema develop-
ment in COPD has been described since 2000 and early [15, 16]. And the inter-
est of researchers to the problem of the involvement of the endothelium in the 
pathogenesis of COPD has not decreased over the past decades. So, for the request 
“endothelium + emphysema” (in the title and/or abstract), the well-known online 
resource of the library PubMed offers 117 publications, of which 23 after 2015. For 
the request “endothelium + COPD,” it offers 335 publications, of which 72 after 
2015, and for the request “endothelium + smoking,” it offers 1859 publications, 
of which 188 after 2015. This indicates the relevance of this area of research and 
demonstrates the hopes of researchers finding new opportunities for therapeutic 
and prophylactic effects on this relationship in the pathogenesis of tobacco-related 
lesions, COPD, and emphysema [17–23].
All disorders begin with local and systemic inflammation, hypoxia and oxidative 
stress, and lead to an imbalance of proteases-antiproteases, loss of recovery and 
destruction of lung tissue. Activation and dysfunction of the endothelium involves, 
first of all, imbalance of the endothelium and its associated mechanisms, which 
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are due to the following disorders in the pathogenesis of COPD [4]. Separately, we 
would like to pay attention on some endothelium-dependent factors.
Prolonged damage to endotheliocytes by aggression factors (persistent inflam-
mation, hypoxia, oxidative stress, an imbalance in the protease-antiprotease system, 
etc.) leads to their death and anatomical reduction of the capillary bed, which is a 
component of emphysematous lung changes. Pathobiology of small vessels in COPD, 
in addition to inflammatory and hypercoagulative changes, is characterized by 
intimal thickening, arteriole muscularization, a decrease in the number of capillar-
ies, and a decrease in blood vessels [13, 15]. Delivering a VEGF receptor (VEGFR) 
antagonist to rats led rapidly to air space enlargement and pruning of the pulmonary 
arterial tree [23, 24]. VEGF is a trophic factor that is crucial for the survival of 
endothelial cells. The experiment demonstrated that prolonged blockade of VEGF 
receptors leads to apoptosis of septal endothelial cells and emphysema [16, 25]. 
Subsequent studies of emphysematous lungs confirmed that COPD patients have 
decreased lung levels of VEGF, reduced expression of VEGFR in pulmonary endo-
thelial cells and apoptotic alveolar septal cells, and reduced expression of hypoxia-
inducible factor-1α (HIF-1α), a transcription factor that drives the expression of 
genes involved in endothelial function including VEGFRs [26, 27]. It has been shown 
that along with the progression of emphysema, degenerative changes in the walls of 
the aorta develop, including its dilatation and aneurysmatization [28, 29]. These facts 
indicate that among other circumstances, an important role in the pathogenesis of 
emphysema belongs to endotheliocytes and VEGF. Moreover, it has been described 
that the presence of emphysema in patients with COPD is associated with a reduced 
content of сirculated endothelial cells, an endothelial repair factor [11, 30].
Endothelial dysfunction and damage are also caused by the acute effects of 
cigarette smoke long before the development of emphysema in animal models. 
Brief exposure of mice to cigarette smoke exacerbates lipopolysaccharide- and 
Pseudomonas aeruginosa-induced acute lung injury in vivo, and cigarette smoke 
extract increases the permeability of endothelial monolayers in vitro [14, 27]. 
Moreover, a recent study identified cigarette smoke-induced apoptosis of endo-
thelial cells in the lungs of mice exposed chronically to cigarette smoke and COPD 
patients [11]. Thus, data from both animal models of COPD and COPD patients 
and controls support the hypothesis that endothelial dysfunction and injury are key 
processes in the pathogenesis of emphysema.
In Table 1 we composed information on key endothelium-related agents that 
take into account the mechanisms of emphysema development in COPD, well 
described previously [4, 10–13, 18–20, 22, 23, 26, 27].
The mechanisms of the inclusion of neurokinins and related substances in 
neurogenic inflammation and destruction at different stages of COPD are much less 
known. Moreover, in recent studies, descriptions of the neuro-mediated mecha-
nisms for the development of emphysema in COPD and smoking have become 
recognized.
It is known that tobacco smoke is a powerful inducer of the destruction of the 
respiratory epithelium throughout, followed by its morphofunctional remodeling 
[4, 31, 32]. Initiation of cell and tissue injury processes in prolonged exposure to 
smoking can take place due to excess release of neurotransmitters from sensitive 
afferent nerve fibers of the nervous vagus system. A large proportion (75%) of 
such fibers belong to the type of nonmyelinated or C-fibers, the sources of which 
are small neurons of the knotted and jugular ganglia, which synthesize neuropep-
tide transmitters or neurokinins (such as substance P (SP), a peptide genetically 
related to calcitonin (CGRP) and neurokinin (A)) [33, 34]. Afferent influences 
are primarily aimed at maintaining the structural and functional homeostasis of 
the respiratory system by stimulating the secretion of mucus from the submucous 
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glands and goblet cells, contractility of smooth muscles, vascular permeability, 
modulation of immune cascades, etc. [34–36]. It is known that afferent fibers 
(C-fibers) are extremely sensitive to the effects of irritants that make up tobacco 
smoke [37]. In a situation of prolonged and/or intense stimulation of sensory 
Components Origin, localization Physiological effects and potential role at 
pathogenesis emphysema in COPD
Nitric oxide (NO) In main, endothelial cells and 
other cells
Vasorelaxation, vasoprotection, anti-
inflammatory, anti-adhesion, reparation. 
Endothelin antagonist
Endothelinum-1 (ET-1) Endothelial cells, bronchial 
epithelium, alveolar 
macrophages
Activates receptors on smooth cells, 
encouraging stable vasoconstriction and 
increase of endothelium adhesively
sPECAM-1 Endothelial cells, 
lymphocytes, platelets, 
macrophages, granulocytes, 
T/NK-cell megakaryocytes, 
fibroblasts, osteoclasts
Plays a basic role in lymphocyte adhesion to 
vascular wall with followed effects
Selectins: E-selectin 
(CD62Е), Р-selectin 
(CD62Р), L-selectin 
(CD62L)
Activated endothelial cells Regulation of leukocyte adhesion 
(strengthens the capacity to migration, 
leukocyte adhesion to activated 
endothelium in inflammation)
Thrombomodulin 
(CD141)
Endothelial cells Interacts with thrombin, activates protein 
C, acts as anticoagulant across activation 
factors fVa, fVIIIа, fXa, and fXIIIa
Circulated endothelial 
cells
Endothelial cells from 
vascular wall, activated bone 
marrow
Can be as the factor of reparation according 
to inflammatory processes and as the factor 
of injury to the endothelium and other 
tissues due to activated phenotype
Vascular endothelial 
growth factor (VEGF)
Endothelial cells Main inductor of angiogenesis, VEGF, 
provides their effects across receptors’ 
endothelial cell and expression of 
VEGF regulated by hypoxia, chronic 
inflammation, hypercoagulation, etc. 
In chronic processes, function can be an 
imperfect character
Stimulates apoptosis and phagocytosis and 
promotes development of emphysema
Neutrophil elastase 
(catepsin G, proteinase 3)
Neutrophils, monocytes, Т 
lymphocytes, endothelial cells, 
vascular smooth muscles cells
Decreases migration of T lymphocytes and 
neutrophil to inflammation area, factor of 
decelerating of phagocytosis. Function from 
protection to damaging. Can cause damage 
to tissues, development of emphysema, and 
mucus hypersecretion
Involved in normal degradation of matrix 
proteins elastin, collagen, fibronectin, 
laminin, and proteoglycans
Matrix 
metalloproteinases 
(ММP-1, ММP-2, 
ММP-9)
Endothelial cells, 
macrophages, neutrophils, 
monocytes, fibroblasts, 
keratinocytes, osteoblasts
Contributes to release TNF-α from 
macrophages, that results to neutrophils 
recruiting and production neutrophil 
elastase, that leads to damage tissues, 
development emphysema. Involved 
in degradation of type IV collagen, 
fibronectin, and elastin
Table 1. 
Endothelium-related Components of emphysema development in COPD and smoking [4, 10–13, 18–20, 22, 23, 26, 27].
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Agents Origin, localization Physiological effects and potential role 
in emphysema pathogenesis in COPD
References
Neurokinins 
Substance P 
(SP)
Sensitive nerve 
endings. SP receptors 
on respiratory and 
glandular epithelial 
cells and endothelial 
cells.
Neurokinin receptor-1 
affixed to SP is found 
in submucous glands, 
and SP release from 
nociceptive nerves 
is responsible for 
secretion of glands
Belongs to the family of tachykinins, 
sensory peptides. Induces vasodilation 
and transudation of blood plasma in the 
respiratory tract.
Induces chemotaxis of monocytes, 
neutrophils, and eosinophils and 
stimulates macrophages to produce 
mediators of inflammation and 
neutrophil elastase.
Powerful mast cell stimulator, causing 
their degranulation. Sources and release 
of histamine and cytokine synthesis 
(IL-6). Takes part in neurogenic 
inflammation when stimulating the 
production of IgA from B lymphocytes 
and cytokines from T-helper cells.
Enhances the release of acetylcholine 
from the postganglionic cholinergic 
nerves of the respiratory tract
It causes smooth muscle contraction, 
secretion of submucous glands, 
vasodilation, and increased vascular 
permeability.
Tobacco smoking inhibits the activity 
of the enzyme endopeptidase, which 
enhances the activity of SP
[40, 45,  
48, 49]
Neurokinins 
Neurokinin А
The highest density 
in the nerve fibers 
around the arteries. 
Tachykinin receptor 
subtypes NK1, NK2, 
and NK3
Belongs to the family of tachykinins, 
sensory peptides. Contraction of smooth 
muscles; secretion of submucous 
glands; vasodilation; increased 
vascular permeability; stimulation of 
cholinergic nerves, mast cells, B and 
T lymphocytes, and macrophages; 
eosinophil chemoattraction; and adhesion 
of neutrophils in the vessels of the 
respiratory tract with activation following
[44, 50, 51]
Neuropeptide 
-γ
It is produced in some 
of the upper cervical 
ganglia and the bodies 
of the main palatine 
cells
Sympathetic nerves 
contain either 
norepinephrine or 
norepinephrine and 
neuropeptide Y
Reduces the frequency of vibrations 
of ciliary cells induced by cholinergic 
nerves, providing an inhibitory effect on 
these nerves
Sympathetic reflexes cause 
vasoconstriction and can also stimulate 
the secretion of certain glands in the 
trachea and bronchi
[38, 39, 48]
Receptor NK1 NK1 tachykinin 
receptor mRNA 
is found in the 
pulmonary arteries, 
veins, and human 
bronchi, in the 
endothelium of the 
veins and arteries, and 
in the smooth muscles 
of the bronchi, as well 
as in lymphocytes, 
macrophages, and 
mastocytes
The tachykinin receptor NK1, with the 
highest affinity for SP. SP, in turn, is a 
powerful mast cell stimulator, causing 
their degranulation, and induces the 
chemotaxis of monocytes, neutrophils, 
eosinophils, and stimulates macrophages 
to produce inflammatory mediators and 
neutrophilic elastase
[40, 42, 45]
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fibers, excessive release of neuropeptide mediator is accompanied by a number 
of plastic and destructive processes due to a cascade of pathological reactions of 
neurogenic inflammation [38, 39]. In addition to substance P of neuronal origin, 
neuropeptides from cells of the immune system—eosinophils, basophils, mono-
cytes, macrophages and lymphocytes—join the realization of neurogenic inflam-
mation [38, 40, 41]. The obtained data indicate the role of the disturbance of the 
activity of the neurokinin system in the development and maintenance of mor-
phofunctional changes in the pathology of the respiratory tract associated with 
smoking [42–46]. Chronic exposure to cigarette smoke has been shown to increase 
SP expression in neurons of the central nervous system [35–37] and simultane-
ously inhibits the activity of enzymes that metabolize neurokinins [39, 40, 43].  
According to experimental study, even low concentrations of cigarette smoke 
significantly reduce the topical activity of neuronal endopeptidase and increase 
the concentration of CP in the respiratory tract [35]. The contribution of excessive 
sensitivity of NK1 receptors in the airways to the development of bronchocon-
striction under the influence of tobacco smoke irritants and/or during bronchial 
asthma has been proven [42, 43, 47]. At the same time, the components and 
mechanisms of neurogenic inflammation in the development of emphysema 
associated with prolonged exposure to tobacco smoke are poor and fragmentary in 
the literature.
In Table 2 we have tried to compose information about potential neuro-medi-
ated mechanisms of emphysema development in COPD and tobacco smoking.
3.  Mechanisms of neurogenic inflammation in the tissue remodeling 
processes in emphysema: own researches
3.1  Study of the neurogenic inflammation mechanisms in the emphysema 
formation in the experiment
To study the contribution of the components of neurogenic inflammation 
to the processes of tissue remodeling in pulmonary emphysema associated with 
smoking, an experimental model of long-term tobacco smoking in vivo in rats 
was reproduced. The experiment was performed in appliance with the model 
D. According to Zheng [53] in our own modification [54], the duration of expo-
sure to tobacco smoke in terms of human life is 12 years. The features of the 
Agents Origin, localization Physiological effects and potential role 
in emphysema pathogenesis in COPD
References
Receptor NK2 
Receptor NK3
NK2 receptor mRNA 
is abundantly 
expressed in the 
human bronchi 
and weakly in the 
pulmonary veins and 
arteries
NK3 tachykinin 
receptor mRNA 
is found in the 
pulmonary arteries, 
veins, and human 
bronchi
The tachykinin receptor NK2, with the 
highest affinity for neurokinin A.
Tachykinin receptor NK3, with the 
highest affinity for neurokinin B
The release of histamine from mouse 
mast cells is mediated through tachykinin 
NK2 receptors
[40, 42,  
45, 52]
Table 2. 
Potential neuro-mediated mechanisms of emphysema development in COPD and tobacco smoking.
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distribution and activity of SP, NK1, MMP-2, MMP-9, and TIMP-2 in the tissues 
of the mucous membrane of the lungs were performed using the immunoper-
oxidase method on cryostat sections of 15 μm in thickness according to standard 
methods. The following primary antibodies were used: anti-SP (Abcam, ab 14184, 
1:200, США), anti-NK1 (Chemicon AB 5060, 1:500, USA), anti-MMP2 (rabbit 
polyclonal, ThermoScientific), anti-MMP9 (rabbit polyclonal, ThermoScientific, 
rb-9234-p, 1:200), anti-TIMP2 (rabbit polyclonal, Abcam, ab61224, 1:100), second-
ary biotinylated antibodies (ThermoScientific, 1:200), streptavidin peroxidase 
(ThermoScientific), and chromogen (Peroxidase Substrate Kit, VectorNovaRED, 
SK-4800). Morphological studies were performed in the laboratory of the Pacific 
State Medical University.
The results of morphological studies of the bronchopulmonary system of rats in 
the control group and with the model of long-term tobacco smoking are presented 
in Figure 1.
Morphological changes in the lungs of rats with a long-term tobacco smoking 
model are focal. Over the entire area of the slice of the lungs, there are fields with 
pronounced emphysematous changes, accompanied by loss of the integrity of the 
alveoli and the formation of large emphysematous expansions, an increase in the 
thickness of the interalveolar septa (Figure 1B, D). In other parts of the lung paren-
chyma, there are signs of swelling and/or hemorrhagic impregnation in peribron-
chial spaces. Cellular composition contains cells of immune inflammation—plasma 
cells, lymphocytes, and macrophages.
The distribution of the components of the neurokinin system of rats obtained 
by morphological examination of the bronchi and lungs coincides with the previ-
ously described data [55] and is shown in Figure 2. Nerve fibers secreting SP are 
presented in the subepithelial zones of the bronchi (Figure 2A); their penetration is 
recorded in the epithelial layer (Figure 2B), pulmonary parenchyma (Figure 2D), 
and adventitia of pulmonary vessels (Figure 2E).
The morphometry of the components of the neurokinin system in the bron-
chopulmonary system of rats was compared with the model of long-term tobacco 
smoking and control animals (Table 3).
Figure 1. 
The lung (A, B) and bronchi (C, D) of animals in the control group (A, C) and rats with the DTC model 
(B, D). Coloring: hematoxylin-eosin. Scale: A, B (500 microns); C, D (100 microns).
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The content of SP-containing fibers and NK1-positive structures in the control 
group and in the model of long-term tobacco smoking shows an ambiguous pattern. 
An increase in the distribution area of SP-immunopositive nerve fibers in the lungs 
and bronchi of experimental animals was found to be 10.7 and 9.4%, respectively, 
compared with the control group. The most significant increase in fiber density was 
observed in the adventitia of pulmonary parenchyma vessels compared with other 
structures. Being a vasodilator, substance P increases vascular permeability and 
promotes adhesion and penetration of leukocytes into the surrounding tissues for the 
realization of local immune reactions involved in the development of destructive pro-
cesses in the pulmonary parenchyma. Regarding NK1-positive elements, it should be 
noted that there is no change in their content in the lung tissue and a moderate increase 
in the density in the bronchial wall against the background of a decrease in the total 
number and NK1-immunoreactive tissue basophils. Obviously, substance P plays a key 
role in the implementation of neurogenic inflammation processes in chronic exposure 
to tobacco smoke. The established pattern of changes in NK1-positive structures can 
be explained by the ability of SP to cause mast cell degranulation and NK1 receptor-
dependent release of histamine and serotonin involved in local inflammatory answer.
Figure 2. 
Distribution of SP- and NK1-reactive structures in the bronchopulmonary system of rats. Coloring: 
immunoperoxidase reaction on SP; repainting, hematoxylin-eosin. Scale: A, 100 microns; B–E, 50 microns.
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One of the leading stimulators of the synthesis of substance P in the model 
of long-term tobacco smoking is hypoxia which changes the humoral regulation 
of blood flow [55]. SP can adjust the change in vessel diameter at the unchanged 
vascular wall using an axon reflex for adequate blood flow at a given point in time. 
However, when the architectonics of the vascular wall changes, the SP loses its func-
tion as a regulator and can participate in both excessive vasodilation and paradoxi-
cal vasoconstriction.
In the development of the structural remodeling of the respiratory system, there 
are several morphological phenomena that accompany this process and are the basis 
for the development of reversible and irreversible morphofunctional changes. These 
include thinning of the epithelial layer, development of subepithelial fibrosis, an 
increase in smooth muscle thickness, an increase in the number and/or size of the 
submucosal glands, and the activation of angiogenesis processes [56]. In the patho-
genesis of the changes taking place, great importance is attached to the activity of the 
enzymes of the extracellular matrix, which ensure the degradation of its interstitial 
proteins. Modern advances in proteomics have shown that for normal development, 
physiological renewal, restoration of healthy tissues, and the formation of pathological 
changes in tissue morphology, two groups of proteins are leading—MMPs and their 
tissue inhibitors [57, 58]. MMPs are a family of 20 zinc and calcium-dependent endo-
peptidases capable of cleaving almost all components of the extracellular matrix of 
connective tissues [59]. The level of synthesis and secretion of MMP into the extracel-
lular space is regulated by transcription factors, and their proteolytic activity depends 
on the chemical transformations of the enzyme molecule in the interstitial space. As 
a result, either activation of the proenzymes or inhibition of their active forms can be 
observed. Depending on the type of protein metabolized, MMP can be divided into 
collagenases (MMP-1, MMP-8, and MMP-13), gelatinase (MMP-2 and MMP-9), stro-
malins (MMP-3 and MMP-10), etc. [60, 61]. In mammals there are four known TIMPs 
that inhibit all MMPs in a 1:1 ratio by strong covalent bonding [62]. It is believed that 
the balance of proteolytic and antiproteolytic mechanisms maintained in different 
tissues and organs is carried out by a specific set of intercellular matrix enzymes and 
their inhibitors [59, 63]. On the other hand, each process has a specific set of depressed 
matrix proteolytic enzymes. In this regard, great prospects in creating targeted therapy 
for many pathological processes are associated with the determination of the tissue 
specificity of the enzymes of the extracellular matrix and the identification of patterns 
of changes in their activity during the development of pathology.
Indicator Bronchi Lungs
Control Experiment 
(long-term 
smoking model)
Control Experiment (long-
term smoking model)
SP distribution area (%) 5.11 ± 
0.36
5.59 ± 0.14* 4.60 ± 
0.29
5.10 ± 0.34*
NK1 distribution area (%) 0.27 ± 
0.03
0.31 ± 0.03* 0.16 ± 
0.016
0.16 ± 0.02
NK1-positive mast cells (in 
1 mm3 of the tissue)
92.68 ± 
19.26
76.39 ± 15.74*
General population of tissue 
basophils (in 1 mm3 of the 
tissue)
129.53 ± 
19.64
106.93 ± 7.64*
*The differences are significant with р < 0.05.
Table 3. 
Morphometric characteristics of SP- and NK1-immunoreactive structures in the bronchopulmonary system of rats.
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A number of studies have shown the role of individual types of MMP in the 
development of nicotine-associated pathology of the lungs and bronchi [57, 58]. 
To clarify the role of the leading MMP—MMP9 related to the inducible form and 
MMP2—considered as a constitutive variant of the enzyme in the development of 
pulmonary emphysema associated with long-term smoking, we studied the immu-
nohistochemical and biochemical content of enzymes in the tissues and homog-
enates of rats with long-term smoking patterns (Figure 3).
In the bronchopulmonary system of rats, prolonged exposure to tobacco smoke 
is accompanied by ambiguous dynamics of the content of matrix metalloproteinases 
and their inhibitors. Normally, the activity of MMP-2 and MMP-9 is recorded in the 
cytoplasm and processes of bronchial and pulmonary fibroblasts, which form a thin 
MMP-positive strip in the lamina propria of the bronchial mucosa (Figure 3A, B) 
and in the interalveolar septa (Figure 3C). In the lungs and bronchi of rats with the 
long-term tobacco smoking model, a marked decrease in the immunohistochemical 
activity of MMP-2 and MMP-9 was observed. At the same time, in the acute phase of 
the experiment, the number and intensity of coloring of immunopositive structures on 
MMP-2 and MMP-9 are higher than in the control group. According to the quantitative 
Figure 3. 
Immunohistochemical (A–C) and biochemical determination of MMP in the bronchopulmonary system of rats 
with a model of long-term tobacco smoking. Coloring—immunohistochemical reaction to MMP-2 and MMP-9. 
Scale: A, B, B—50 μm. Localization of MMP-2 in the wall of the bronchus (A, B) and interalveolar septa (C). 
(D) Zymogram of MMP-2 and MMP-9. Lanes 1–4, lung homogenates of rats of the control group; lanes 5–8, 
lung homogenates of rats with a model of long-term tobacco smoking.
Indicators Control Experiment (long-
term smoking model)
Control Experiment (long-term 
smoking model)
ММР-9 ММР-2
Conventional 
density units
742689.75 450081.25* 367243.25 246414.75*
ММР-9/ММР-2 2.02 (control) 1.83 (experiment (long-term smoking 
model))
*The differences are significant with р < 0.05.
Table 4. 
The contents of MMP-2 and MMP-9 in the homogenates of the lungs of rats.
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determination of enzymes in the homogenates of lung tissue (Figure 3D, Table 4),  
the resulting trend is confirmed. That is, with the development of pulmonary 
emphysema associated with prolonged smoking in the lung tissue, the content of both 
MMPs decreases evenly.
An analysis of the immunohistochemical composition of the tissue inhibitor 
of both MMP and TIMP-2 showed a marked decrease in its representation in the 
structures of the bronchopulmonary system of animals on a model of long-term 
smoking (Figure 4).
In intact animals, the enzyme localization occurs in the respiratory epithelial 
cells of the bronchial membrane (Figure 4C, indicated by arrows) and fibroblasts 
of the interalveolar septa (Figure 4B). In animals of the main group, the overall 
intensity of immunohistochemical staining of lung tissue decreases, and at high 
magnifications of the microscope, it is possible to fix a significant depression of the 
color or complete disappearance of the enzyme content in the epithelial lining cells 
of the bronchi and lung parenchyma tissue (Figure 4, indicated by arrows).
According to the data obtained, the immunolocalization of MMP-2, MMP-9, 
and TIMP-2 repeats the basic pattern of distribution of pro-inflammatory cells 
and coincides with the foci of the most noticeable rearrangements of the connec-
tive tissue of the bronchi and the pulmonary parenchyma. In the acute phase of 
the experiment, the activity of the markers is significantly higher compared to the 
control; after 6 months of exposure to smoke, there is a decrease of the proteolytic 
activity and at the same time the processes of its inhibition.
3.2  Study of the neurogenic inflammation mechanisms of the emphysema 
formation in humans
In addition to studying the processes of neurogenic inflammation and the 
contribution of matrix metalloproteinases to the development of emphysema in the 
Figure 4. 
The distribution of the content of TIMP-2 in the lungs of rats of the control (A–C) and with the model of long-
term tobacco smoking (D) groups. Coloring—immunohistochemical reaction to TIMP-2. Scale A, 100 microns; 
GD, 50 microns. A total enzyme content in the tissues of the bronchopulmonary system. B-TIMP-2-positive 
fibroblasts of the interalveolar septa. B-content of the enzyme in the epithelial cells of the small bronchus 
(indicated by arrows). G-reduction of the enzyme content in epithelial cells of the bronchus of rats with a 
model of prolonged smoking (indicated by arrows).
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experiment, we analyzed the content of neurokinin system markers, the localiza-
tion, and the content of MMP-2, MMP-9, and TIMP-2 in human lung tissue struc-
tures. Morphological studies of autopsy material were performed on 12 individuals 
aged 51–65 years and 3 women and 9 men, average age 61.5 ± 4.14 years, who died 
a sudden death outside the hospital. The long-term history of tobacco smoking was 
clarified from the close relatives and on the basis of the data of the outpatient card. 
Features of the distribution and activity of SP, NK1, MMP-9, and TIMP-2, in lung 
tissues were investigated using the immunoperoxidase method on cryostat sections 
Figure 5. 
Distribution of the content of SP (A, C, E, G) and NK1 (B, D, F, H) in the bronchopulmonary system in 
persons with emphysema. Coloring: immunohistochemical reaction to SP and NK1, stained with hematoxylin. 
Scale: A, B, E, G (50 microns); C, D (100 microns); and F, H (20 microns). Nerve fibers innervating the 
wall of the bronchus (A) and interalveolar partitions (C). Localization of SP-positive macrophages in 
peribronchial infiltrates (E). SP-positive glandulocytes of the bronchial glands (G). Localization of neurokinin 
receptors on the surface of peribronchial macrophages (B), dust macrophages (D), vascular endothelial cells 
(F), and chondrocytes of the fibrocartilage membrane of the bronchi (H).
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of 15 μm in thickness according to the standard procedure using the primary 
antibody line described above.
In lung tissue and bronchial wall of patients with pulmonary emphysema, 
positive SP immunoreactivity is found mainly in the nerve fibers (Figure 5). More 
common are single conductors having a uniform ribbonlike course and numerous 
varicose thickenings. With a successful coincidence of the cut plane with the spatial 
geometry of the fibers, it is possible to observe beams extending 300–500 μm. Fibers 
penetrate through the walls of the bronchi of medium and small caliber, spread 
around the perimeter of the submucosa (Figure 5A, B). In the interstitial tissue, 
lightweight fibers have a diameter of 0.5–1 microns, and sometimes they are grouped 
into clusters with the formation of numerous terminals. Probably, the latter are 
areas of the most dense accumulation of neuromuscular and glandular contacts. The 
morphological characteristics of the colored conductors allow them to be treated as 
mixed (afferent and motor) fibers. High SP expression is also detected in peribron-
chial leukocyte infiltrates (Figure 5D). Here, high immunoreactivity is observed 
for neurokinin receptors of type 1 (Figure 5B, D). The preferential localization of 
the NK1 surface of the membranes of the secretory epithelial cells of the bronchial 
glands, alveolar and stromal macrophages, microvascular endothelial cells, and ele-
ments of the fibrocartilage membrane (Figure 5B, D, E, H) should be emphasized.
Prolonged pathological effects of tobacco combustion products entail the forma-
tion of structural changes with the active involvement of the neurokinin innerva-
tion apparatus localized in the mucous membranes of the respiratory system. The 
increase in the number of macrophage cells and NK1-positive macrophages, and 
the direct interaction between them and afferent fibers, through terminals, sug-
gests the involvement of sensory nerve fibers in the regulation of local immune, 
Figure 6. 
Localization of MMP-9 in the lungs (A, B) of a person. Coloring: immunohistochemical reaction to MMP-9, 
stained with hematoxylin. Scale: A (50 microns); B (100 microns).
Figure 7. 
Localization of TIMP-2 pulmonary parenchyma in individuals with emphysema. Coloring: 
immunohistochemical reaction to TIMP-2, stained with hematoxylin. Scale: 100 microns.
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inflammatory, and destructive processes in the lung tissue during smoking-induced 
emphysema.
In contrast to the experimental data, in individuals with long periods of smok-
ing and emphysema, there is an increase in the immunohistochemical density of 
MMP-9 in the pulmonary parenchyma (Figure 6), while TIMP-2 is practically 
undetermined (Figure 7).
In this way, from the presented data of experimental modeling of emphysema 
associated with long-term smoking, as well as studies in people with pulmonary 
emphysema and long-term tobacco smoking experience, neurogenic inflamma-
tion takes an active part in the processes of remodeling of lung tissue. Markers of 
neuro-mediated inflammation activity are overexpression of SP-containing nerve 
fibers, the presence of NK-1-tagged macrophages, mast cell degranulation, and an 
immune-mediated pattern of inflammatory infiltrate. Pathomorphosis of pulmo-
nary parenchyma destruction in nicotine-associated pulmonary emphysema is 
associated with dysregulation in the state of the family of matrix metalloprotein-
ases. In the acute period of exposure to tobacco combustion products, overexpres-
sion of MMP-9 is observed with suppression of the activity of the tissue inhibitor 
TIMP-2, followed by depression of the tissue content of both MMP-2 and MMP-9 
and an inhibitor of their activity TIMP-2. In individuals with pulmonary emphy-
sema, the MMP-9 tissue pattern retains its excessive representation.
4. Conclusions and future directions
Results from human and animal studies indicate that endothelial dysfunction 
and injury contribute not only to the genesis and progression of pulmonary lesions 
in COPD (especially emphysema development) but may also contribute to some of 
the common comorbidities and systemic effects reported in COPD patients. Vascular 
endothelium initiates and modulates the main pathomorphic processes in COPD and 
smoking. In particular, endothelium activation is an important factor of initiation, 
development and persistence of inflammation, and vessel and tissue remodeling, 
in particular emphysema. It is not by chance that the relationship of emphysema 
of the lungs is described in violation of the mechanical properties of the aorta and 
excessive stiffness of other exponents’ bloodstream [4, 6, 64]. At the basis of these 
pathological processes are common (genetically determined and pathologically 
determined) mechanisms associated with impaired collagen-elastin metabolism.
The latest studies are conducted in the direction of studying not simple, 
associated with the endothelium, but specific neuro-mediated mechanisms of 
emphysema development in COPD and smoking. Our studies presented in this 
chapter describe the study of the processes of neurogenic inflammation and the 
contribution of matrix metalloproteinases to the development of emphysema in the 
experiment and in humans.
We are confident that there is a special morphofunctional continuum in the 
development of lower respiratory tract remodeling in response to chronic exposure 
to tobacco smoke and the development of inflammation in COPD. New data suggest 
that imbalance of neuro-mediated interactions, alteration of vasomotoric signaling 
mechanisms, secretion, mucociliary clearance, cytoprotection involving substance 
P-dependent components with impaired content, and development of dystopia of 
matrix metalloproteinases and their tissue inhibitors are involved in the initiation of 
morphological restructuring. Future studies should also assess the extent to which 
endothelial dysfunction and injury, particularly neuro-mediated mechanisms, 
underlie emphysema in COPD and smoking as target to therapeutic and prophylac-
tic impacts.
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